Biohaven Ltd. (BHVN) Price & Analysis

Compare

822 Followers

BHVN Stock Chart & Stats

$10.54

-$0.59(-1.49%)

At close: Jan 08 4:00 PM EST

$10.54

-$0.59(-1.49%)

Day’s Range― - ―

52-Week Range$7.48 - $44.55

Previous CloseN/A

Volume146.24K

Average Volume (3M)5.11M

Market Cap

$1.23B

Enterprise Value$1.64B

Total Cash (Recent Filing)$260.22M

Total Debt (Recent Filing)$314.18M

Price to Earnings (P/E)―

Beta1.61

Next Earnings

Mar 19, 2026

EPS Estimate

-1.23

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.64

Shares Outstanding129,188,490

10 Day Avg. Volume2,725,084

30 Day Avg. Volume5,105,180

Financial Highlights & Ratios

PEG Ratio-0.06

Price to Book (P/B)8.05

Price to Sales (P/S)0.00

P/FCF Ratio-5.81

Enterprise Value/Market Cap1.33

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-1.49K

Enterprise Value/Ebitda-2.08

Forecast

1Y Price Target

$15.09

Price Target Upside43.17% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering13

EPS Forecast (FY)-6.74

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Financial PositionBiohaven’s $175M offering also alleviates a near-term financing overhang and provides a cushion to reaching potential value-driving readouts.

Pipeline DevelopmentBiohaven's prioritized pipeline now consists of the Kv7, degrader, and myostatin programs, with depression data expected and Phase III epilepsy data being significant milestones.

Strategic FocusBiohaven is implementing strategic portfolio and cost-optimization initiatives to focus on three late-stage clinical programs with the highest potential for value.

Bears Say

Competitive DisadvantageBHVN is 2+ years behind competitor Xenon in primary indication for Kv7, diminishing its competitive edge.

Market ConfidenceThe stock is downgraded to Neutral, with a price target lowered to $11, reflecting a decrease in confidence due to regulatory hurdles.

Regulatory ChallengesBiohaven received a Complete Response Letter from the FDA for its NDA for Troriluzole in spinocerebellar ataxia.

Biohaven Ltd. News

Biohaven downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded Biohaven (BHVN) to Neutral from Buy with a price target of $11, down from $30....

8d ago

BHVN

Midday Fly By: Dell, HP move in opposite directions after earnings

Stocks are higher near noon as traders lean into the idea that the Federal Reserve is ready to...

14d ago

Autodesk upgraded, Nio downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

14d ago

Biohaven downgraded to Neutral from Buy at UBS

UBS downgraded Biohaven (BHVN) to Neutral from Buy with a price target of $11, down from $26. The...

15d ago

BHVN

Biohaven price target lowered to $15 from $47 at JPMorgan

JPMorgan lowered the firm’s price target on Biohaven (BHVN) to $15 from $47 and keeps an Overweight rating...

21d ago

BHVN

Biohaven call volume above normal and directionally bullish

Bullish option flow detected in Biohaven (BHVN) with 1,855 calls trading, 1.3x expected, and implied vol increasing over...

22d ago

BHVN

Biohaven price target lowered to $26 from $54 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Biohaven (BHVN) to $26 from $54 and keeps an Overweight...

22d ago

BHVN

Biohaven price target lowered to $14 from $28 at Citi

Citi lowered the firm’s price target on Biohaven (BHVN) to $14 from $28 and keeps a Buy rating...

28d ago

BHVN

Biohaven 23.33M share Spot Secondary priced at $7.50

J.P. Morgan, Goldman Sachs & Co., Leerink Partners, TD Cowen and Cantor are acting as book-running managers of...

28d ago

BHVN

Closing Bell Movers: AMD up 5% after unveiling medium term targets

In the opening hour of the evening session, U.S. equity futures are up marginally, with S&P 500 e-minis...

29d ago

ALC

Cautious Hold Rating on Biohaven Ltd. Amidst R&D Setbacks and Competitive Challenges

In a report released today, Ashwani Verma from UBS maintained a Hold rating on Biohaven Ltd., with a...

15d ago

BHVN

Strategic Adjustments and Future Potential: Biohaven Ltd. Receives Buy Rating Amidst Regulatory Challenges

Terence Flynn, an analyst from Morgan Stanley, maintained the Buy rating on Biohaven Ltd.. The associated price target...

23d ago

BHVN

Strategic Positioning and Growth Potential Drive Buy Rating for Biohaven Ltd.

Analyst Thomas Shrader from BTIG maintained a Buy rating on Biohaven Ltd. and keeping the price target at...

23d ago

BHVN

Biohaven Ltd. Raises $200M in Public Offering

Biohaven Ltd. ( ($BHVN) ) just unveiled an update. On November 12, 2025, Biohaven Ltd. entered into an...

27d ago

BHVN

BHVN FAQ

What was Biohaven Ltd.’s price range in the past 12 months?

Biohaven Ltd. lowest stock price was $7.48 and its highest was $44.55 in the past 12 months.

What is Biohaven Ltd.’s market cap?

Biohaven Ltd.’s market cap is $1.23B.

When is Biohaven Ltd.’s upcoming earnings report date?

Biohaven Ltd.’s upcoming earnings report date is Mar 19, 2026 which is in 98 days.

How were Biohaven Ltd.’s earnings last quarter?

Biohaven Ltd. released its earnings results on Nov 10, 2025. The company reported -$1.64 earnings per share for the quarter, beating the consensus estimate of -$1.901 by $0.261.

Is Biohaven Ltd. overvalued?

According to Wall Street analysts Biohaven Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Biohaven Ltd. pay dividends?

Biohaven Ltd. does not currently pay dividends.

What is Biohaven Ltd.’s EPS estimate?

Biohaven Ltd.’s EPS estimate is -1.23.

How many shares outstanding does Biohaven Ltd. have?

Biohaven Ltd. has 129,188,490 shares outstanding.

What happened to Biohaven Ltd.’s price movement after its last earnings report?

Biohaven Ltd. reported an EPS of -$1.64 in its last earnings report, beating expectations of -$1.901. Following the earnings report the stock price went down -5.69%.

Which hedge fund is a major shareholder of Biohaven Ltd.?

Currently, no hedge funds are holding shares in BHVN

Biohaven Ltd. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-522.08%

Trailing 12-Months

Asset Growth

-19.86%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Biohaven Ltd.

Biohaven Ltd. (BHVN) is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapies for neurological and neuropsychiatric diseases. The company operates in the healthcare sector and specializes in addressing unmet medical needs within the central nervous system (CNS) disorders. Biohaven's core products include FDA-approved treatments for migraine and other CNS conditions, leveraging its proprietary platforms and extensive research capabilities.

Biohaven Ltd. (BHVN) Earnings & Revenues

Historic Earnings Reports

BHVN Stock 12 Month Forecast

Average Price Target

$15.09

▲(43.17% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","45":"$45","17.25":"$17.25","26.5":"$26.5","35.75":"$35.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.09,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.09</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,17.25,26.5,35.75,45],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.32,10.910769230769231,12.501538461538463,14.092307692307692,15.683076923076923,17.273846153846154,18.864615384615384,20.455384615384617,22.046153846153846,23.636923076923075,25.22769230769231,26.818461538461538,28.409230769230767,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.32,9.763846153846155,10.207692307692309,10.651538461538461,11.095384615384615,11.53923076923077,11.983076923076924,12.426923076923078,12.87076923076923,13.314615384615385,13.758461538461539,14.202307692307691,14.646153846153847,{"y":15.09,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.32,9.295384615384616,9.27076923076923,9.246153846153847,9.221538461538461,9.196923076923078,9.172307692307692,9.147692307692308,9.123076923076923,9.098461538461539,9.073846153846153,9.04923076923077,9.024615384615384,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":44.74,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.35,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.25,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.18,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.6,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.68,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.96,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.71,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.89,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.82,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.32,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >